GlycoMimetics Inc (GLYC)
0.3168
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 16:00
0.3133
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Cash from Investing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | -0.0025M |
| March 31, 2024 | -0.0074M |
| December 31, 2023 | -0.0008M |
| September 30, 2023 | -0.0079M |
| June 30, 2023 | -0.0105M |
| March 31, 2023 | -0.0022M |
| December 31, 2022 | -0.00 |
| September 30, 2022 | -0.0025M |
| June 30, 2022 | -0.0412M |
| March 31, 2022 | -0.0405M |
| December 31, 2021 | -0.0024M |
| September 30, 2021 | -0.0043M |
| June 30, 2021 | -0.0051M |
| March 31, 2021 | -0.0031M |
| December 31, 2020 | -0.0382M |
| September 30, 2020 | -0.0158M |
| June 30, 2020 | -0.0064M |
| March 31, 2020 | -0.0081M |
| December 31, 2019 | -0.0124M |
| September 30, 2019 | -0.0183M |
| June 30, 2019 | -0.0748M |
| March 31, 2019 | -0.0395M |
| December 31, 2018 | -0.057M |
| Date | Value |
|---|---|
| September 30, 2018 | -0.0266M |
| June 30, 2018 | -0.0254M |
| March 31, 2018 | -0.0166M |
| December 31, 2017 | -0.0342M |
| September 30, 2017 | -0.0327M |
| June 30, 2017 | -0.1642M |
| March 31, 2017 | -0.063M |
| December 31, 2016 | -0.4386M |
| September 30, 2016 | -0.2254M |
| June 30, 2016 | -0.023M |
| March 31, 2016 | -0.0173M |
| December 31, 2015 | -0.0032M |
| September 30, 2015 | -0.0584M |
| June 30, 2015 | -0.2046M |
| March 31, 2015 | -0.0023M |
| December 31, 2014 | -0.0149M |
| September 30, 2014 | -0.102M |
| June 30, 2014 | -0.0818M |
| March 31, 2014 | -0.0139M |
| December 31, 2013 | -0.0124M |
| September 30, 2013 | -0.0392M |
| June 30, 2013 | -0.0237M |
| March 31, 2013 | -0.0068M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.0412M
Minimum
Jun 2022
--
Maximum
Sep 2024
-0.0106M
Average
-0.0057M
Median
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Arbutus Biopharma Corp | -11.99M |
| Revance Therapeutics Inc | 23.29M |
| FibroGen Inc | 0.755M |
| Cidara Therapeutics Inc | -0.106M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.994M |
| Free Cash Flow | -35.02M |
| Free Cash Flow Per Share (Quarterly) | -0.124 |
| Free Cash Flow Yield | -171.5% |